ArticleJournal of advanced pharmaceutical technology & research
Solubility improvement of atorvastatin using deep eutectic solvents.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep eutectic solvents (DESs) in pharmaceutical investigations are still largely unknown in terms of safety, environmental acceptability, and practical use. The investigation focus is primarily of attempts to improve solubility is examined using the co-crystallization approach, which follows similar principles to the production of eutectic mixtures. We will look into the eutectic mixture interaction between selected coformers (nicotinamide [NA], isonicotinamide, and citric acid as acceptors of hydrogen bond and atorvastatin calcium trihydrate [ATCH] as donors of hydrogen bond in the DES system, assisted by propylene glycol [PG]). The study found that the optimum interaction in the DES system for ATCH is using NA in PG as a carrier, with evaluation by polarization microscopy, Fourier transform infrared spectroscopy (FT-IR), and differential scanning calorimetry (DSC), verifying that the drug and the DES components have formed H-bonds. H-bond interactions had been recognized through FT-IR and DSC, revealing that the DESs with NA coformer can increase ATCH solubility, as shown in the phase diagram. The increase in solubility was fairly considerable, allowing ATCH to dissolve at high concentrations in DESs, with a solubility of 0.158 ± 0.098 mg/mL compared to 0.000597 ± 0.003 mg/mL in water. Thus, it is obtainable to conclude that among the selected coformers, the DES system with the potential for improving the solubility of ATCH is DESs with NA coformer assisted by PG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.